123 related articles for article (PubMed ID: 6357429)
1. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
D'Incalci M; Torti L; Damia G; Erba E; Morasca L; Garattini S
Cancer Res; 1983 Dec; 43(12 Pt 1):5674-80. PubMed ID: 6357429
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
Ferrari A; Damia G; Erba E; Rossi C; Mandelli R; D'Incalci M
Int J Cancer; 1989 Jun; 43(6):1091-7. PubMed ID: 2659542
[TBL] [Abstract][Full Text] [Related]
3. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
4. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
5. Activity of 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt in M 5076/73A ovarian reticular cell sarcoma of the mouse.
Colombo T; Garattini S; Lassiani L; D'Incalci M
Cancer Treat Rep; 1982 Nov; 66(11):1945-8. PubMed ID: 6754075
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
Tagliabue G; Filippeschi S; Hendricks H; D'Incalci M
Ann Oncol; 1992 Mar; 3(3):233-6. PubMed ID: 1586622
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
Frondoza CG; Trivedi SM; Humphrey RL
Cancer Treat Rep; 1982 Jul; 66(7):1535-44. PubMed ID: 7093969
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
10. [Effect of Ganoderma lucidum polysaccharides on tumor cell nucleotide content and cell cycle in S180 ascitic tumor-bearing mice].
Li JJ; Lei LS; Yu CL; Zhu ZG; Zhang Q; Wu SG
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1003-5. PubMed ID: 17666337
[TBL] [Abstract][Full Text] [Related]
11. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
12. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
Schmid FA; Otter GM; Stock CC
Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
[TBL] [Abstract][Full Text] [Related]
13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
15. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
16. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
17. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
Hickman JA; Stevens MF; Gibson NW; Langdon SP; Fizames C; Lavelle F; Atassi G; Lunt E; Tilson RM
Cancer Res; 1985 Jul; 45(7):3008-13. PubMed ID: 4005840
[TBL] [Abstract][Full Text] [Related]
18. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A
Anticancer Res; 1988; 8(6):1351-4. PubMed ID: 3064716
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
Bellet RE; Danna V; Mastrangelo MJ; Berd D
J Natl Cancer Inst; 1979 Nov; 63(5):1185-8. PubMed ID: 91697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]